TheraRadar
Data updated: May 26, 2026

GILDESS 24 FE (ethinyl estradiol)

Women's Health Approved 2014-12-01

Gildess 24 Fe is a combination oral contraceptive (COC) indicated for use by females of reproductive potential to prevent pregnancy. It contains two active hormonal components: norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen). This 24-day regimen also includes seven ferrous fumarate (iron) tablets to be taken during the hormone-free interval.

Source: FDA Label • PH HEALTH

How GILDESS 24 FE Works

Gildess 24 Fe prevents pregnancy primarily by suppressing ovulation. Secondary mechanisms include thickening of the cervical mucus, which inhibits sperm penetration, and alterations in the endometrium, which may reduce the likelihood of implantation.

Source: FDA Label
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Discontinued
First Approved
2014-12-01
Routes
ORAL
Dosage Forms
TABLET

Companies

GILDESS 24 FE Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2014 to 2025
Jul 2025 SUPPL
Label · Labeling
Dec 2014 ORIGINAL
Update

What GILDESS 24 FE Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)

GILDESS 24 FE Boxed Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Iclevia, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: CIGARETTE SMOKING AND SERIOUS C...

📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 not yet recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GILDESS 24 FE FDA Label Details

Indications & Usage

Iclevia TM (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. Iclevia is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy.

⚠️ BOXED WARNING

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For th...

Track GILDESS 24 FE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.